Anzeige
❌
Mehr »
Sonntag, 04.10.2026 - Börsentäglich über 12.000 News
Die Lizenz, über die niemand spricht, und warum Wettbewerber keine bekommen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PT

WKN: A40EDR | ISIN: US46489V3024 | Ticker-Symbol: AAJ0
Tradegate
01.10.26 | 17:17
2,388 Euro
-2,45 % -0,060
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4362,46603.10.
2,3902,50402.10.

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPerspective Therapeutics, Inc.: Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 202689SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...
► Artikel lesen
DoPerspective Therapeutics, Inc. - 8-K, Current Report1
18.09.William Blair startet Coverage für Perspective Therapeutics mit "Outperform"6
18.09.William Blair initiates Perspective Therapeutics stock with outperform rating1
16.09.Perspective Therapeutics auf Morgan Stanley Konferenz: Offensive bei Alpha-Strahlen-Therapie5
14.09.Perspective Therapeutics partners with Merck on cancer trial4
14.09.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors552SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...
► Artikel lesen
PERSPECTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
08.09.Perspective Therapeutics, Inc. - 8-K, Current Report2
19.08.BMO initiates Perspective Therapeutics stock at Outperform, $11 target3
10.08.Perspective Therapeutics GAAP EPS of -$0.22 beats by $0.04, revenue of $0.08M misses by $0.01M4
10.08.Perspective Therapeutics, Inc. - 8-K, Current Report1
10.08.Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results297Advancing VMT-a-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject...
► Artikel lesen
07.08.Perspective Therapeutics Q2 2026 Earnings Preview3
31.07.Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results1
29.07.Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now2
28.07.Perspective Therapeutics, Inc.: Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs248European orphan medicinal product designation granted for [212Pb]VMT-a-NET for the treatment of GEP-NETs[212Pb]VMT-a-NET is being evaluated in an ongoing Phase 1/2a study in patients with SSTR2-positive...
► Artikel lesen
24.07.BTIG reiterates Perspective Therapeutics stock rating on manufacturing edge5
24.07.BTIG: Produktionsvorteil stützt Kaufempfehlung für Perspective Therapeutics5
17.07.Perspective Therapeutics, Inc.: Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Oral Presentation at the ESMO Congress 20262
08.07.Perspective Therapeutics, Inc.: Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor270SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering...
► Artikel lesen
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1